
CLAIMS

What is claimed is:

1. A compound having the formula:



(I),

or a pharmaceutically acceptable salt thereof, wherein

R^1 is C_{1-3} aliphatic;

R^2 is hydrogen, fluoro, or methyl;

R^3 is hydrogen, fluoro, or methyl;

each R^4 is, independently, hydrogen or fluoro; and

R^5 is hydrogen, chloro, cyclopropyl, or C_{1-4} aliphatic, optionally substituted with 1-3 fluorine atoms.

2. The compound according to claim 1, wherein R^2 is methyl and R^3 is hydrogen.

3. The compound according to claim 2, wherein R^1 is methyl and R^5 is hydrogen.

4. The compound according to claim 1, wherein R^2 is hydrogen and R^3 is methyl.

5. The compound according to claim 4, wherein R^1 is methyl and R^5 is hydrogen.









6. The compound according to claim 1, wherein each of R^2 and R^3 is fluoro.

7. The compound according to claim 6, wherein R^1 is methyl and R^5 is hydrogen.

8. The compound according to any one of claims 1 to 7, wherein R^4 is hydrogen.

9. The compound according to any one of claims 1 to 7, wherein R^4 is fluoro.

10. The compound according to claim 1 having the following structure:

,
,
,
,
,
,
,
, or

11. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

12. The composition according to claim 11, additionally comprising a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an agent for treating atherosclerosis, or an agent for treating lung fibrosis.

13. A method of treating or lessening the severity of a proliferative disorder in a patient comprising administering the compound according to claim 1, or a pharmaceutical composition comprising said compound, in an amount sufficient to treat or lessen the severity of said proliferative disorder in said patient.


14. The method according to claim 13, wherein said disorder is metastatic cancer.

15. The method according to claim 13, wherein said disorder is a glioblastoma; a gastric carcinoma; or a cancer selected from colon, breast, prostate, brain, liver, pancreatic or lung cancer.

16. The method according to claim 13, wherein said disorder is hepatocellular carcinoma.

What is claimed is:

1. The compound having the formula:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

3. The composition according to claim 2, additionally comprising a chemotherapeutic or anti-proliferative agent.